Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 3
Submit an article Journal homepage
644
Views
1
CrossRef citations to date
0
Altmetric
Coronavirus

Acceptance of COVID-19 boosters among hypertensive patients in China: A multicenter cross-sectional study

Ying Yana National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. ChinaView further author information
,
Qingyuan Chenc The First Clinical Medical College, Capital Medical University, Beijing, P.R. ChinaView further author information
,
Abudulimutailipu Nuermaimaitia National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. China;d National Center for Clinical Laboratories, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. ChinaView further author information
,
Yingzi Xiaoa National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. China;d National Center for Clinical Laboratories, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. ChinaView further author information
,
Le Changa National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. ChinaView further author information
,
Huimin Jia National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. ChinaView further author information
,
Huizhen Suna National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. ChinaView further author information
,
Qinggang Songe Department of Cardiology, Xi’an No.1 hospital, Xi’an, Shaanxi,P.R. ChinaCorrespondence[email protected]
View further author information
,
Yuanfeng Gaof Heart Center & Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. ChinaCorrespondence[email protected]
View further author information
,
Junjie Xug Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen, Guangdong, P.R. ChinaCorrespondence[email protected]
View further author information
&
Lunan Wanga National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing,P.R. China;b Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing,P.R. China;d National Center for Clinical Laboratories, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2283315 | Received 17 Jul 2023, Accepted 10 Nov 2023, Published online: 20 Nov 2023

References

  • Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Gimenez-Roqueplo A-P, Hering D, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet commission on hypertension. Lancet. 2016;388(10060):2665–13. doi:10.1016/S0140-6736(16)31134-5.
  • Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785–802. doi:10.1038/s41569-021-00559-8.
  • NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80. doi:10.1016/S0140-6736(21)01330-1.
  • Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137(22):2344–56. doi:10.1161/CIRCULATIONAHA.117.032380.
  • Zhang M, Wu J, Zhang X, Hu CH, Zhao ZP, Li C, Huang ZJ, Zhou MG, Wang LM. Prevalence and control of hypertension in adults in China, 2018. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42:1780–9. doi:10.3760/cma.j.cn112338-20210508-00379.
  • Chenchula S, Vidyasagar K, Pathan S, Sharma S, Chavan MR, Bhagavathula AS, Padmavathi R, Manjula M, Chhabra M, Gupta R, et al. Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression. Sci Rep. 2023;13(1):6415. doi:10.1038/s41598-023-33314-9.
  • Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–18. doi:10.1016/j.jaci.2020.04.006.
  • Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. doi:10.1001/jamainternmed.2020.0994.
  • Chen J, Liu Y, Qin J, Ruan C, Zeng X, Xu A, Yang R, Li J, Cai H, Zhang Z. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study. Postgrad Med J. 2022;98(1161):515–22. doi:10.1136/postgradmedj-2021-140674.
  • Nashiry A, Sarmin Sumi S, Islam S, Quinn JMW, Moni MA. Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities. Brief Bioinform. 2021;22(2):1387–401. doi:10.1093/bib/bbaa426.
  • Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi:10.1177/1470320320926899.
  • Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Sig Transduction Targeted Ther. 2022;7:146. doi:10.1038/s41392-022-00996-y.
  • WHO. COVID-19 vaccine tracker and landscape [Internet]. [accessed 2023 Apr 25]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
  • Wang G, Yao Y, Wang Y, Gong J, Meng Q, Wang H, Wang W, Chen X, Zhao Y. Determinants of COVID-19 vaccination status and hesitancy among older adults in China. Nat Med. 2023;29(3):623–31. doi:10.1038/s41591-023-02241-7.
  • China CDC. COVID-19 situation reports on February 15, 2023. [Internet]. [accessed 2023 Feb 20]. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/t20230215_263756.html.
  • National Health Commission of the People’s Republic of China. Issues about COVID-19 booster vaccination [Internet]. [accessed 2023 Apr 28]. http://www.nhc.gov.cn/xcs/s7847/202111/67a59e40580d4b4687b3ed738333f6a9.shtml.
  • Ying C-Q, Lin X-Q, Lv L, Chen Y, Jiang J-J, Zhang Y, Tung T-H, Zhu J-S. Intentions of patients with hypertension to receive a booster dose of the COVID-19 vaccine: a cross-sectional survey in Taizhou, China. Vaccines (Basel). 2022;10(10):1635. doi:10.3390/vaccines10101635.
  • Tung T-H, Lin X-Q, Chen Y, Zhang M-X, Zhu J-S. Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China. Expert Rev Vaccines. 2022;21(2):261–7. doi:10.1080/14760584.2022.2016401.
  • Wang X, Liu L, Pei M, Li X, Li N. Willingness of the general public to receive a COVID-19 vaccine booster - China, April-May 2021. China CDC Wkly. 2022;4:66–70. doi:10.46234/ccdcw2022.013.
  • The joint prevention and control mechanism of the State Council. second dose of SARS-CoV-2 booster vaccination implementation program [Internet]. [accessed 2023 Feb 20]. http://www.gov.cn/xinwen/2022-12/14/content_5731899.htm.
  • The US FDA. Vaccines and related biological products advisory Committee January 26, 2023 meeting briefing document- FDA | FDA [Internet]. [accessed 2023 Apr 28]. https://www.fda.gov/media/164699/download.
  • Couzin-Frankel J. New COVID-19 vaccine strategy would mimic flu’s annual shots. Science. 2023;379(6631):425–6. doi:10.1126/science.adg9446.
  • Townsend JP, Hassler HB, Dornburg A. Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting. J Med Virol. 2023;95(2):e28461. doi:10.1002/jmv.28461.
  • The US FDA. Updated COVID-19 vaccines for use in the United States beginning in fall 2023. FDA [Internet]; 2023 [accessed 2023 Oct 16]. https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023.
  • MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4. doi:10.1016/j.vaccine.2015.04.036.
  • Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination hesitancy. BMJ. 2021;373. doi:10.1136/bmj.n1138.
  • Carico R, Sheppard J, Thomas CB. Community pharmacists and communication in the time of COVID-19: applying the health belief model. Res Social Adm Pharm. 2021;17:1984–7. doi:10.1016/j.sapharm.2020.03.017.
  • Wang H, Huang Y-M, Su X-Y, Xiao W-J, Si M-Y, Wang W-J, Gu X-F, Ma L, Li L, Zhang S-K, et al. Acceptance of the COVID-19 vaccine based on the health belief model: a multicenter national survey among medical care workers in China. Hum Vaccin Immunother. 2022;18(5):2076523. doi:10.1080/21645515.2022.2076523.
  • Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccin Immunother. 2020;16(9):2204–14. doi:10.1080/21645515.2020.1790279.
  • Limbu YB, Gautam RK, Pham L. The health belief model applied to COVID-19 vaccine hesitancy: a systematic review. Vaccines (Basel). 2022;10(6):973. doi:10.3390/vaccines10060973.
  • Zampetakis LA, Melas C. The health belief model predicts vaccination intentions against COVID-19: a survey experiment approach. Appl Psychol Health Well Being. 2021;13:469–84. doi:10.1111/aphw.12262.
  • Zhou HJ, Pan L, Shi H, Luo JW, Wang P, Porter HK, Bi Y, Li M. Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China. Front Pharmacol. 2022;13:1013485. doi:10.3389/fphar.2022.1013485.
  • Wang J, Lyu Y, Zhang H, Jing R, Lai X, Feng H, Knoll MD, Fang H. Willingness to pay and financing preferences for COVID-19 vaccination in China. Vaccine. 2021;39(14):1968–76. doi:10.1016/j.vaccine.2021.02.060.
  • Bai X, Chen L, Liu X, Tong Y, Wang L, Zhou M, Li Y, Hu G. Adult hepatitis B virus vaccination coverage in China from 2011 to 2021: a systematic review. Vaccines (Basel). 2022;10(6):900. doi:10.3390/vaccines10060900.
  • Hou Z, Chang Null J, Yue D, Fang H, Meng Q, Zhang Y. Determinants of willingness to pay for self-paid vaccines in China. Vaccine. 2014;32(35):4471–7. doi:10.1016/j.vaccine.2014.06.047.
  • China’s NHSA. National healthcare security administration: costs of routine COVID-19 nucleic acid tests born by the local governments [Internet]. [accessed 2023 Oct 17]. https://www.gov.cn/xinwen/2022-05/26/content_5692466.html.
  • Tung T-H, Lin X-Q, Chen Y, Zhang M-X, Zhu J-S. Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China. Hum Vaccin Immunother. 2022;18:2099210. doi:10.1080/21645515.2022.2099210.
  • Sj P, Yp Y, Mx Z, Th T. Willingness to pay for booster dose of COVID-19 vaccine among healthcare workers in Taizhou,China. Hum Vaccines Immunother [Internet]. 2022 [accessed 2023 Oct 17];18. doi:10.1080/21645515.2022.2063629.
  • 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision Committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16:182–241.
  • China CDC. COVID-19 situation reports on April 22, 2023. [Internet]. [accessed 2023 Apr 26]. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202304/t20230422_265534.html.
  • Jiang N, Yang C, Yu W, Luo L, Tan X, Yang L. Changes of COVID-19 knowledge, attitudes, practices and vaccination willingness among residents in Jinan, China. Front Public Health. 2022;10:917364. doi:10.3389/fpubh.2022.917364.
  • Wang J, Yuan B, Lu X, Liu X, Li L, Geng S, Zhang H, Lai X, Lyu Y, Feng H, et al. Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China. Hum Vaccin Immunother. 2021;17(12):4873–88. doi:10.1080/21645515.2021.2009290.
  • Nehal KR, Steendam LM, Campos Ponce M, van der Hoeven M, Smit GSA. Worldwide vaccination willingness for COVID-19: a systematic review and meta-analysis. Vaccines (Basel). 2021;9:1071. doi:10.3390/vaccines9101071.
  • Yin D, Chen H, Deng Z, Yuan Y, Chen M, Cao H, Zhou X, Luo J, Zhang W, Gu Z, et al. Factors associated with COVID-19 vaccination acceptance among industrial workers in the post-vaccination era: a large-scale cross-sectional survey in China. Hum Vaccin Immunother. 2021;17(12):5069–75. doi:10.1080/21645515.2021.1989912.
  • Ramot S, Tal O. Attitudes of healthcare workers in Israel towards the fourth dose of COVID-19 vaccine. Vaccines (Basel). 2023;11(2):385. doi:10.3390/vaccines11020385.
  • Duan L, Wang Y, Dong H, Song C, Zheng J, Li J, Li M, Wang J, Yang J, Xu J. The COVID-19 vaccination behavior and correlates in diabetic patients: a health belief model theory-based cross-sectional study in China, 2021. Vaccines (Basel). 2022;10(5):659. doi:10.3390/vaccines10050659.
  • Caspi I, Freund O, Pines O, Elkana O, Ablin JN, Bornstein G. Effect of patient COVID-19 vaccine hesitancy on hospital care team perceptions. World J Clin Cases. 2023;11(4):821–9. doi:10.12998/wjcc.v11.i4.821.
  • Lai X, Zhu H, Wang J, Huang Y, Jing R, Lyu Y, Zhang H, Feng H, Guo J, Fang H. Public perceptions and acceptance of COVID-19 booster vaccination in China: a cross-sectional study. Vaccines (Basel). 2021;9(12):1461. doi:10.3390/vaccines9121461.
  • Simonini M, Scarale MG, Tunesi F, Manunta P, Lanzani C, Di Serio PC, Moro DM, Multidisciplinary Epidemiological Research Team Study Group. COVID-19 vaccines effect on blood pressure. Eur J Intern Med. 2022;105:109–10. doi:10.1016/j.ejim.2022.08.027.
  • Zappa M, Verdecchia P, Spanevello A, Visca D, Angeli F. Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. Eur J Intern Med. 2021;90:111–13. doi:10.1016/j.ejim.2021.06.013.
  • Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G. CHUV COVID vaccination center. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension. 2021;77(6):e56–7. doi:10.1161/HYPERTENSIONAHA.121.17316.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.